Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection

Cytokine Growth Factor Rev. 2013 Dec;24(6):571-7. doi: 10.1016/j.cytogfr.2013.07.001. Epub 2013 Aug 17.

Abstract

Interleukin 27 (IL-27) is an immunomodulatory cytokine with important roles in both the innate and adaptive immune systems. In the last five years, the addition of exogenous IL-27 to primary cell cultures has been demonstrated to decrease HIV-1 replication in a number of cell types including peripheral blood mononuclear cells (PBMCs), CD4+ T cells, macrophages and dendritic cells. These in vitro findings suggest that IL-27 may have therapeutic value in the setting of HIV-1 infection. In this review, we describe the current knowledge of the biology of IL-27, its effects primarily on HIV-1 replication but also in other viral infections and explore its potential role as a therapeutic cytokine for the treatment of patients with HIV-1 infection.

Keywords: Cytokines; HIV; Interleukin-27; SPTBN1; Therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV-1 / drug effects
  • HIV-1 / physiology
  • Humans
  • Interleukin-27 / chemistry
  • Interleukin-27 / immunology*
  • Interleukin-27 / pharmacology
  • Receptors, Interleukin / chemistry
  • Receptors, Interleukin / immunology
  • Virus Diseases / drug therapy

Substances

  • IL27RA protein, human
  • Interleukin-27
  • Receptors, Interleukin